Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar Showcasing Alcohol Metabolism Beverage Opportunity
Unbuzzd Wellness, licensee of Quantum BioPharma, will host an investor webinar on September 16, 2025, to present clinical data and sales strategies for its scientifically proven alcohol metabolism beverage, highlighting a significant investment opportunity in the growing wellness market.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its licensee Unbuzzd Wellness will host an Investor Webinar on September 16, 2025, at 1:30 p.m. PT, featuring company leadership who will outline the current Reg D 506(c) investment opportunity. The webinar will review clinical data and highlight strategies to accelerate direct-to-consumer, distributor, and retail sales of unbuzzd(TM), the scientifically proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
The event gains significance as it represents a strategic opportunity in the growing wellness beverage market, with Quantum BioPharma retaining substantial financial interests through its licensing agreement. According to the arrangement detailed in the company's filings, Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity.
This investor webinar matters because it showcases a product addressing the substantial market for alcohol-related wellness solutions, with clinical data supporting its efficacy. The presentation by CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will provide investors with critical insights into both the scientific validation and commercial potential of the technology.
Quantum BioPharma maintains additional rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, positioning the company for potential expansion into medical markets beyond the current consumer product. Investors can access the latest news and updates relating to QNTM through the company's newsroom at https://ibn.fm/QNTM.
The broader implications of this development extend to the biopharmaceutical sector's increasing focus on consumer wellness products with scientific backing. As companies seek to monetize research through multiple channels, the unbuzzd(TM) model demonstrates how pharmaceutical innovation can translate into commercially viable consumer products while maintaining pathways for future medical applications.